Scinai Immunotherapeutics LTD

Mark Germain, a Director at Scinai Immunotherapeutics Ltd., acquired 120,000,000 ordinary shares through a grant of restricted share units.

SCNI CEO Amir Reichman has acquired 400,000,000 ordinary shares through restricted share units (RSUs) granted on June 16, 2026.

LCK JNK 1 LLC has reported beneficial ownership of 317,366 American Depository Shares, representing 6.33% of Scinai Immunotherapeutics Ltd.'s outstanding shares, as of April 27, 2026.

An amended Schedule 13G filing reveals updated beneficial ownership details for Scinai Immunotherapeutics Ltd. by Stone Daniel E. and RK Stone Miami, LLC.

Daniel E. Stone and RK Stone Miami, LLC collectively report a 16.61% beneficial ownership stake in Scinai Immunotherapeutics Ltd. ADSs.

Daniel E. Stone and RK Stone Miami, LLC reported increased beneficial ownership in Scinai Immunotherapeutics Ltd., holding 9.9% and 8.1% respectively.

YA II PN, Ltd. and its affiliates have disclosed a 9.9% beneficial ownership stake in Scinai Immunotherapeutics Ltd. through a Standby Equity Purchase Agreement, allowing the company to sell up to $10 million in ADSs.

LCK JNK 1 LLC has filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Scinai Immunotherapeutics Ltd.'s American Depository Shares.